to induce long-lasting immunity to protect against challenge with tumor cells or clinical regrowth of micrometastatic disease. Because in vivo therapy for patients with cancer using gene transfer would, as a first step, attempt to eliminate the existing tumor, we have investigated whether antitumor immunity induced by tumor cells secreting a single cytokine could be increased by cotransfer of a second cytokine gene. To test this approach, CMS-5, a murine fibrosarcoma, was transduced with retroviral vectors carrying interleukin-2 (IL-2). interferon-7 (IFN-y), or granulocyte-macrophage-colony-stimulating factor (GM-CSF) cDNA alone or IL-2 cDNA in combination with IFN-7 or GM-CSF cDNA. Single cytokine-secreting clones were selected to match levels of cytokine production by double MPROVEMENTS IN THE ability to target the delivery and expression of transgenes in vivo raise the possibility of exploring gene therapy for the treatment of human malignancies.'76 Of several possible approaches to gene therapy for cancer, the introduction of cytokine genes into tumor cells as part of a vaccine strategy has shown efficacy in experimental model^.^-^^ However, results vary depending on the cytokine gene and tumor system chosen. The expression of certain cytokine genes by tumor cells has been shown to increase tumor immunogenicity and has led to primary rejection of transfected tumor cells by syngeneic hosts as well as to the induction of a systemic, cellular antitumor immacrophage-colony-stimulating factor (GM-CSF) do not show an effect on tumor growth in vivo but can lead to potent systemic immunity on challenge with parental tumor cells, when the vaccine is applied as irradiated cytokine-secreting tumor ~e l l s .~~.~~ Tumor cells expressing these cytokines might prove to be important in adjuvant tumor therapy; however, they appear unlikely to benefit patients with a primaq tumor and metastatic disease. Whereas in some tumor systems it has been possible to show rejection of preestablished disease,16*17,26-28 in most animal models, this has not been possible. In initial steps toward in vivo gene therapy for cancer, it is necessary to develop strategies to optimize the stimulation of primary antitumor immunity by cytokine gene-transduced tumor cells. In the present study we investigated the antitumor immune responses induced by single cytokine-secreting tumor cells and the effect of having the tumor cell provide two cytokine-stimulatory signals. We and others have shown that transfection and expression of interferon-y (IFN-y) cDNA can lead to increased expression of cell surface molecules, including major histocompatability complex (MHC) molecules and tumor-associated antigens, and can render nonimmunogenic tumors susceptible to destruction by cytotoxic T ~e l l s .~-l~ Local secretion of interleukin-2 (IL-2) from IL-2 cDNA-transfected tumor cells can activate and expand specific cytotoxic effector cells, cytokine-secreting clones so that similar amounts of cytokine were secreted. IFN-y-and IL-P/IFN-y-secreting CMS-5 cells showed increased levels of major histocompatability complex class I expression compared with IL-2-and GM-CSF-secreting or parental CMS-5 cells, IL-Z/IFNy-secreting CMS-5 cells were always rejected, by syngeneic mice, whereas the same number of CMS-S cells secreting only one of these cytokines or mixtures of single cytokine-secreting CMS-5 cells were not rejected. In vivo depletion of CD4+, CD8'. or natural-killer effector cell subpopulations showed that CD8+ cytotoxic T cells were primarily responsible for rejection of IL-2/IFfU-y-transduced tumor cells. Our data show the successful use of a single retroviral vector to stably transduce two cytokine genes into the same tumor cell, leading to an increased effect on the in vivo induction of antitumor immunity. 0 1994 by The American Society of Hematology.
leading to tumor rejecti~n.~~~.'~ The synergistic interaction of cytokines has been shown in several biologic systems. By transducing a tumor cell with the cDNA's for both IL-2 and IFN-y, we have attempted to induce increased antitumor immunity by activating the afferent as well as the efferent arm of the immune response. IFN-y should act by enhancing the immunogenicity of the target cell and by activating nonspecific cytotoxic effector cells, whereas IL-2 should provide the costimulatory signal necessary to activate and expand cytotoxic T cells, presumably present in close proximity to the transduced tumor ~ells.~'-~~ Because mixing two tumor cell populations (each population secreting one cytokine) could lead to preferential elimination of one of the populations" and, thus, to the premature cessation of the effects of one cytokine, we have decided to express both cytokines by the same tumor cell to increase cellular antitumor response in vivo. Because a single transduction step providing signals for optimum primary rejection would be desirable for in vivo use, we have developed double cytokine retroviral vectors carrying both IL-2 and IFN-y genes or IL-2 and GM-CSF genes and, as controls, single cytokine ret-roviral vectors carrying IL-2, IFN-y, or GM-CSF genes. GM-CSF cDNA were cloned in tained from American Type Culture Collection (Rockvilk MD), orientation into the SnaBI site, and the poly-A signal was cloned produce monoclonal antibodies (MoAbs) reactive with a monointo the Menowed Apa I site of the 3' LTR po~y~inker, To complete meric determinant on the MHC class I molecule and a polymorphic cloning of N/CG"CSF/RIL2 the CMV-GM-CSF"fusion proddeterminant on the MHC class 11 molecules of I-Ab,d haplotypes, UCt was cloned into the Xho I site downstream the neomycin generespectively. After washing twice, cells were incubated with a 150 coding sequences of DC/AD/R/IL2, 36 N2/CMV-GM-CSF was gendilution of fluorescein isothiocyanate-conjugated goat antirat IgG crated by cloning the ,"V-G~-CSF"fusion product into the (Cappel Laboratones, Durham. NC) for 30 minutes at 4°C in the Same Xho I site in the N2 vector, DCA is a previously described dark. The cells were washed twice and then analyzed. Fluorescence vector in which the human ADA minigene was cloned into the 3'
originating from dead cells was excluded by propidium iodide stain-LTR of N2.37 Retroviral vector constructs were converted to the ing and threshold gating of forward and 90" light scatter signals.
corresponding virus by electroporating vector DNA into a helperResults were confirmed by fluorescence microscopy. free, ecotropic (GP+E-86: DC/AD/R/IFNy, DC/AD/R/GM-CSF, Tumor growth in vivo. BALB/c mice were obtained from a col-CSF/RIL2) or amphotropic packaging line 12: injections were performed using freshly prepared tumor cells that DC/TKIL2, ~~) . 3 8 , 3 9 colonies were isolated by (3418 selection were removed from culture plates by trypsinization and washed (0.7 m g / m~ ofGenticin; GIBCO Laboratories, Grand Island, NY) twice in PBS. Cells were injected ID in the back of 7-to IO-weekand were expanded to producer cell lines, and cell-free supernatant old animals. Tumor growth was measured in millirneters was tested for viral titer. For personal use only. on November 11, 2017. by guest www.bloodjournal.org From DOUBLE CYTOKINE RETROVIRAL VECTORS were administered, starting l week before tumor cell injection. For natural killer (NK)-cell depletion, 30 p L of rabbit antiasialo GM1 serum (Wako Chemicals, Richmond, VA) was injected intraperit* neally (P) every 5 days, starting 5 days before tumor cell injection. NKcell depletions were confirmed by in vitro analysis of spleen cell cytotoxicity against the NK-target cell line YAC-l .
RESULTS
Infection of tumor cells and secretion of cytokines. The structures of the retroviral vectors used to transduce the CMS-5 murine fibrosarcoma cells are shown in Fig 1. Viruscontaining, cell-free supernatants of infected packaging cell clones were used to infect NIH 3T3 fibroblasts to determine virus titer. Virus titers of different constructs varied and were correlated inversely with the complexity of the retroviral construct used ( Table 1) . Viral titers for double cytokine constructs ranged from IO3 to IO5 Neo colony-forming units (CFU)/mL, those of single cytokine constructs from IO5 to lo6 Neo CFU/mL. High titer clones were selected to infect CMS-5 fibrosarcoma cells. G4 1 8-resistant CMS-5 clones were screened for expression of transfected cytokine genes by measuring IL-2, GM-CSF, and IFN-y release into the culture supernatant using a bioassay. The results were then confirmed by ELISA. CMS-5 parental cells did not secrete any of the cytokines tested in this study. Clonal isolates of cytokine-gene-transduced CMS- Table 2 ). Secretion of IL-2, IFN-y, or GM-CSF had no discernible effect on cell morphology. No change in growth rate in vitro of GM-CSF-or IL-2/GM-CSF-secreting CMS-5 cells was observed as compared with that for parental CMS-5 cells. Growth rate in culture was slightly reduced by the secretion of IFN-y (Fig 2) .
MHC expression on IFN-r-transduced tumor cells. Augmentation of a specific antitumor response by IL-2 and IFN-y. To study the in vivo effects of IL-2, IFN-y, and GM-CSF secretion on primary tumor rejection, cytokinesecreting or parental CMS-5 cells were injected ID into the back of BALB/c mice, and tumor growth was measured. We previously showed that injection of 2 X lo5 unmodified CMS-5 cells into BALB/c mice results in tumor growth in 100% of mice.' Therefore, we used 2. Fig 5) . Thus, the cosecretion of IL-2 and IFN-y from the same tumor cells seems to augment the primary host antitumor responses compared with that for single cytokine secretion. Because GM-CSF has proven to be a potent inducer of immunity against a challenge of parental tumor cells, we have investigated the direct in vivo effects of GM-CSF-secreting fibrosarcoma cells. CMS-5 bulk-transduced cells secreting high, medium, or low amounts of GM-CSF did not regress at a dose of 2.5 X lo5 cells (Fig 6) . Moreover, the results suggest that GM-CSF secretion by CMS-5 fibrosarcoma cells might even have promoted tumor growth. To show continuing cytokine secretion in vivo, GM-CSF-secreting tumors were removed after 3 to 4 weeks and reestablished in culture, and production of cytokine was measured before and after 10 days of culture with G4 18. GM-CSF secretion before injection corresponded in all cases to the amount secreted after resection ofthe tumor and after G4 18 selection (data not shown). These data suggest that GM-CSF production was responsible for the in vivo observed effects. Ongoing in vivo experiments using CMS-5 cells transduced 
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Fig 2. Proliferation of parental andvector-transduced CMS-6 cells in vitro is shown.
For personal use only. on November 11, 2017. by guest www.bloodjournal.org From with vectors carrying the IL-2 cDNA alone or GM-CSF plus IL-2 cDNAs show that the secretion of GM-CSF, in addition to IL-2, has no further effect on tumor growth inhibition compared with that for IL-2 alone (data not shown).
To investigate whether the antitumor activity induced in N/CIL2/TIFNyCMS5 injected mice was a systemic, longlasting tumor-specific response, mice that had previously re- These results suggested that, in the primary rejection of IL-2/IFN-y-secreting tumor cells, CD8+ cytotoxic T cells were mainly responsible, but NK cells were also induced and that, whereas they were not necessary for elimination of the tumor, they may also influence tumor reject i~n .~~ CD4+ cells did not seem to play a role in the antitumor activity mediated by IL-2/IFN-y-secreting CMS-5 cells.
DISCUSSION
In this report, we investigate the mechanisms of primary rejection of tumor cells transduced with cytokine genes presented in single or double cDNA-containing retroviral constructs. Although it is currently not possible to target therapeutic genes to tumor cells in situ, progress in the development of tissue-specific delivery and expression systems make this a realistic approach in the future.'& Because in vivo treatment of patients with cancer using gene transfer would try to achieve maximum induction of antitumor immunity by a single transduction step, we have investigated whether the cotransduction oftwo cytokines into one tumor cell by a single retroviral vector would lead to an increased host antitumor response. We chose IFN-y and IL-2 in this study, because these cytokines have previously shown efficacy in inducing primary tumor rejection"" and both act on different levels of the immune response. IFN-y is a cytokine known to upregulate molecules that participate in processing and presentation of antigen and, thus, acts on the levels of the target To this end, we constructed single-cytokine retroviral vectors carrying the murine IFN-y, murine GM-CSF, or human IL-2 cDNA and double-cytokine retroviral vectors containing both the IL-2 and IFN-y or IL-2 and GM-CSF cDNA and used those to infect CMS-5, a weakly immunogenic fibrosarcoma. Our data show that retroviral vectors carrying two cytokine genes can be used to stably transfect tumor cells leading to secretion of biologically active pro- Mixing the same numbers of IL-2-and IFN-y-secreting CMS-5 cells also did not result in tumor rejection. This phenomenon may be related to the circumstance that, with the double cytokine vector, both cytokines are secreted at a constant concentration per cell until all tumor cells are destroyed and that, in the cell mixture circumstance, one cytokine-secreting population is preferentially destroyed before the other one. These data support the concept that IL-2 and IFN-y can cooperatively activate cytotoxic functions of the immune system46.63-65 and suggest an advantage to having both cytokines secreted by the same cell. It is possible that in vivo IFN-y-induced upregulation of molecules involved in antigen processing and presentation is more efficacious in the autocrine situation and that more IFN-y would be needed in the paracrine situation. Yet, it has to be considered that, on a per-cell basis, only half as much cytokine is produced in a mixture of clones. The question of the advantage of cosecretion of both cytokines by one tumor cell is not definitely answered with the experiments per- 
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For personal use only. on November 11, 2017. by guest www.bloodjournal.org From moting effect of GM-CSF on CMS-5 cells. Tumor explantation and reselection with G418 in vitro showed that outgrowth of no or low GM-CSF-secreting CMS-5 cells could not be the reason for the observed tumor growth in vivo. In additional experiments, the GM-CSF-containing vector was used to transduce MBT-2, a bladder carcinoma; TS/A, an adenocarcinoma; and B16, a melanoma. In no case did GM-CSF secretion induce rejection of the transduced tumor cells. Our data are in agreement with published data showing that GM-CSF exerts its potent immunostimmulatory effects best if secreted by irradiated tumor cells incapable of proliferation. Dranoff et a124 reported a systemic syndrome of fatal toxicity manifested by leukocytosis, hepatosplenomegaly, and pulmonary hemorrhage in mice injected with live GM-CSF-secreting B 16 cells. This phenomenon was attributed to the progressively increasing number of tumor cells expressing GM-CSF in vivo. Human tumors naturally secreting GM-CSF do not appear to be rejected either. 66 These results and our data underline the importance of carefully selecting the cytokine for each tumor-and gene-therapy approach chosen.
In the absence of cytotoxic CD8' T cells, IL-2/IFN-ysecreting CMS-5 tumors were not rejected, confirming the necessity of CD8' cytotoxic T lymphocytes CTLs for elimination of the tumor. These result suggest that, despite the slight growth inhibition of IFN-y-secreting cells in vitro, direct inhibitory effects of IFN-y on tumor growth were not responsible for tumor regression. Although IL-2/IFNy secretion by tumor cells activated NK cells, as shown by the delayed rejection of tumors in NK-depleted animals, their presence was not necessary to eliminate tumors. CD4+ helper-T cells did not seem to contribute to the rejection of IL-2/IFN-y-secreting CMS-5 cells, because tumor rejection was not impaired in CDCdepleted mice. This impairment was probably caused by constitutive secretion of IL-2 and IFN-y by target cells which bypassed the requirement for helper-T cells.' From the experiments presented here, we cannot exclude that other nonspecific effector cells of the immune system contributed to the rejection of neoplastic cells. IFN-y is a potent macrophage activator and, thus, antitumor activity in this system might be partially attributable to cytostatic or cytotoxic effects of activated macrophages. Moreover, IL-2/IFN-y secretion not only leads to rejection of transduced tumor cells but also stimulates a specific, long-lasting antitumor immunity. This could be clinically important if, after primary therapy, not all tumor cells were eliminated; then, immunity might prevent regrowth of micrometastases. Whether or not the immune response induced by double cytokinetransduced tumor cells might be sufficient to eliminate preestablished disease and how this can be achieved needs further investigation.
In summary, double cytokine-gene-carrying retroviral vectors can be used to stably transfect tumor cells, and augmentation of in vivo antitumor activity can be obtained. Also, expression of both cytokines from one vector construct may be of benefit for future clinical applications to deliver both genes at the same time into one tumor cell. 
